NASDAQ:COLL Collegium Pharmaceutical - COLL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $24.17 +0.02 (+0.08%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$23.25▼$24.3750-Day Range$23.00▼$29.8852-Week Range$14.04▼$30.22Volume164,165 shsAverage Volume510,733 shsMarket Capitalization$823.47 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Collegium Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside44.8% Upside$35.00 Price TargetShort InterestBearish17.38% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment1.34Based on 3 Articles This WeekInsider TradingSelling Shares$2.48 M Sold Last QuarterProj. Earnings Growth22.45%From $5.30 to $6.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector285th out of 1,002 stocksPharmaceutical Preparations Industry122nd out of 488 stocks 3.3 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, Collegium Pharmaceutical has a forecasted upside of 44.8% from its current price of $24.17.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.38% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently increased by 4.20%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 3.5 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Collegium Pharmaceutical this week, compared to 1 article on an average week.Search Interest10 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,484,987.00 in company stock.Percentage Held by InsidersOnly 4.34% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 22.45% in the coming year, from $5.30 to $6.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is -32.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is -32.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCollegium Pharmaceutical has a PEG Ratio of 0.22. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Collegium Pharmaceutical (NASDAQ:COLL) StockCollegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.Read More Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Share Price Passes Below 50 Day Moving Average of $26.62March 20, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Receives New Coverage from Analysts at StockNews.comMarch 28, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 20, 2023 | americanbankingnews.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells $752,082.80 in StockFebruary 26, 2023 | finance.yahoo.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2022 Earnings Call TranscriptFebruary 25, 2023 | seekingalpha.comCollegium Pharmaceutical, Inc. 2022 Q4 - Results - Earnings Call PresentationFebruary 25, 2023 | seekingalpha.comCollegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call TranscriptFebruary 24, 2023 | finance.yahoo.comQ4 2022 Collegium Pharmaceutical Inc Earnings CallMarch 28, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...February 23, 2023 | msn.comCollegium Pharmaceutical Non-GAAP EPS of $1.09 misses by $0.17, revenue of $129.62M beats by $4.41MFebruary 23, 2023 | msn.comCollegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat EstimatesFebruary 22, 2023 | benzinga.comEarnings Outlook For Collegium PharmaceuticalFebruary 22, 2023 | finance.yahoo.comEsperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock DownFebruary 22, 2023 | finance.yahoo.comCollegium Publishes Inaugural 2022 Environmental, Social and Governance ReportFebruary 8, 2023 | msn.comCollegium Pharmaceutical prices $210M senior notesFebruary 8, 2023 | finance.yahoo.comCollegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes OfferingFebruary 7, 2023 | finanznachrichten.deCollegium Pharmaceutical, Inc.: Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial ResultsFebruary 6, 2023 | finance.yahoo.comCollegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial ResultsFebruary 1, 2023 | nasdaq.comFind 'Strong Buy' Stocks Near their Highs for FebruaryJanuary 29, 2023 | seekingalpha.comCollegium Pharmaceutical: Low Multiples Justified, Growth To Come At A CostJanuary 28, 2023 | finance.yahoo.comCollegium Pharmaceutical's (NASDAQ:COLL) investors will be pleased with their decent 62% return over the last yearJanuary 13, 2023 | marketwatch.comPainful Diabetic Neuropathy Drug Market 2023 : Regional Scope, Growth Statistics, Demand and Regional Outlook 2029January 11, 2023 | finance.yahoo.comCOLL vs. ZTS: Which Stock Is the Better Value Option?January 4, 2023 | marketwatch.comCollegium Pharmaceutical Shares Gain 11% on 2023 Guidance, OutlookJanuary 4, 2023 | msn.comCollegium gains on 2023 financial guidance, $100M share buybacksJanuary 3, 2023 | marketwatch.comAllergy Treatment Market 2023 : Trend Analysis, Competitive Outlook of Top Industry Players and Future Expansion by 2028January 3, 2023 | benzinga.comMike Heffernan appointed Chairman of NMD Pharma's Board of DirectorsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Company Calendar Last Earnings2/23/2023Today3/28/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+45.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E Ratio4.55 P/E Growth0.22Net Income$-25,000,000.00 Net Margins-5.39% Pretax Margin-6.22% Return on Equity44.87% Return on Assets7.24% Debt Debt-to-Equity Ratio2.76 Current Ratio0.97 Quick Ratio0.86 Sales & Book Value Annual Sales$463.93 million Price / Sales1.77 Cash Flow$8.28 per share Price / Cash Flow2.91 Book Value$5.80 per share Price / Book4.16Miscellaneous Outstanding Shares34,070,000Free Float32,588,000Market Cap$821.09 million OptionableOptionable Beta0.81 Key ExecutivesJoseph J. CiaffoniPresident, Chief Executive Officer & DirectorColleen TupperChief Financial Officer & Executive Vice PresidentScott SudduthExecutive Vice President-Technical OperationsThomas B. SmithChief Medical Officer & Executive Vice PresidentScott DreyerChief Commercial Officer & Executive VPKey CompetitorsKura OncologyNASDAQ:KURAEnanta PharmaceuticalsNASDAQ:ENTAImmunoGenNASDAQ:IMGNArdelyxNASDAQ:ARDXCrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 2,676 shares on 3/23/2023Ownership: 0.052%Colleen TupperSold 31,640 sharesTotal: $752,082.80 ($23.77/share)Scott DreyerSold 13,324 sharesTotal: $355,750.80 ($26.70/share)State of WyomingSold 4,941 shares on 2/16/2023Ownership: 0.010%Altshuler Shaham LtdBought 1,215 shares on 2/16/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions COLL Stock - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COLL shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price forecast for 2023? 2 analysts have issued 12 month price targets for Collegium Pharmaceutical's stock. Their COLL share price forecasts range from $35.00 to $35.00. On average, they anticipate the company's share price to reach $35.00 in the next year. This suggests a possible upside of 45.2% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2023? Collegium Pharmaceutical's stock was trading at $23.20 on January 1st, 2023. Since then, COLL stock has increased by 3.9% and is now trading at $24.10. View the best growth stocks for 2023 here. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our COLL earnings forecast. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Thursday, February, 23rd. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.10. The specialty pharmaceutical company earned $129.62 million during the quarter, compared to analysts' expectations of $127.07 million. Collegium Pharmaceutical had a negative net margin of 5.39% and a positive trailing twelve-month return on equity of 44.87%. What ETFs hold Collegium Pharmaceutical's stock? ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $569.72 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? (COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. What is Collegium Pharmaceutical's stock symbol? Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL." Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (4.98%), Renaissance Technologies LLC (3.44%), Dimensional Fund Advisors LP (2.74%), Emerald Advisers LLC (2.42%), Emerald Mutual Fund Advisers Trust (2.04%) and Geode Capital Management LLC (1.84%). Insiders that own company stock include Alison B Fleming, Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Collegium Pharmaceutical's stock price today? One share of COLL stock can currently be purchased for approximately $24.10. How much money does Collegium Pharmaceutical make? Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $821.09 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. How many employees does Collegium Pharmaceutical have? The company employs 152 workers across the globe. How can I contact Collegium Pharmaceutical? Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com. This page (NASDAQ:COLL) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.